| Abstrakt: |
Up to 31 October 2020, the TGA approved over 72,000 Special Access Scheme (SAS) Category B applications for unapproved medicinal cannabis products. In June 2020 a multi-clinic open-label observational study registered on the ANZCTR commenced to gather real-world data for patient's using two specific medicines available via the TGA SAS or Authorised Prescribers. The interim results of this observational study available at the time will be presented, including demographics, conditions being managed, efficacy, interactions, adverse events and dosage. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379942&isReview=true [ABSTRACT FROM AUTHOR] |
